Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 15/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | ROS1 | P08922 | 1/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.61 |
| ▸ | CLK2 | P49760 | 1/20 | 0.61 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | MELK | Q14680 | 1/20 | 0.61 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.61 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.61 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8975585 | 1.00 | ADK (1.00) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8975866 | 0.91 | ADK (1.00) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8975325 | 0.86 | ADK (1.00) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8321848 | 0.86 | ADK (0.75) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8328051 | 0.86 | ADK (0.75) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8322892 | 0.84 | ATG7 (0.73) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8975523 | 0.83 | ADK (0.74) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8324823 | 0.83 | ADK (0.71) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8895593 | 0.83 | ATG7 (0.73) | ADKDOT1LDCLK1DAPK3DYRK3 | |
| SCHEMBL8742142 | 0.79 | ADK (0.66) | ADKDOT1LDCLK1DAPK3DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | claimed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | claimed |
| WO-2011075665-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-23 | — | — | WO | claimed |
| EP-0682519-A4 | ADENOSINE KINASE INHIBITORS. | GENSIA INC (US) | 1997-12-17 | — | — | EP | claimed |
| EP-0682519-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1995-11-22 | — | — | EP | claimed |
| WO-1994017803-A9 | ADENOSINE KINASE INHIBITORS | — | 1994-09-29 | — | — | WO | claimed |
| WO-1994017803-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075665-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-0832092-A1 | ORALLY ACTIVE ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040706-A1 | ORALLY ACTIVE ADENOSINE KINASE INHIBITORS | GENSIA-SICOR (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | ADK, AHCY, IAPP | ADK 1/4885DOT1L 502/4885DCLK1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.